Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
2.8
Journals
Genes
Special Issues
Genomics of Glioblastoma: Advances in Diagnosis, Treatment Strategies, and Prognostication
share announcement

Genomics of Glioblastoma: Advances in Diagnosis, Treatment Strategies, and Prognostication

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Neurogenomics".

Deadline for manuscript submissions: closed (5 July 2025) | Viewed by 429

Special Issue Editors

Dr. Ankush Chandra

E-Mail Website
Guest Editor
Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Interests: glioblastoma; genetics; molecular markers; precision medicine; immunotherapy; genomics
Dr. Yoshua Esquenazi

E-Mail Website
Guest Editor
Department Neurosurg, University of Texas Health Science Center Houston, Houston, TX 70030, USA
Interests: epilepsy surgery and surgical neuro-oncology; brain and spine tumors

Special Issue Information

Dear Colleagues,

Glioblastoma multiforme (GBM) remains one of the most challenging cancers to treat due to its aggressive nature, high heterogeneity, and resistance to conventional therapies. Recent advancements in genomic technologies have revolutionized our understanding of GBM, offering insights into its molecular underpinnings and paving the way for personalized medicine approaches. This Special Issue aims to explore the latest developments in the genomics of GBM, focusing on how these insights can enhance diagnosis, prognosis, and treatment strategies.

We invite contributions that delve into genomic alterations and their clinical implications, discussing the identification of key genetic mutations, such as those in IDH1, TP53, and TERT genes, and their impact on patient outcomes. Additionally, we seek articles on molecular subtyping, exploring novel molecular markers and their influence on treatment decisions. Immunotherapy and genomic targeting are also of interest, with studies on how genomic data can inform strategies like immune checkpoint inhibitors, CAR-T cell therapy, and personalized vaccines. Epigenetics and resistance mechanisms, particularly DNA methylation patterns and their role in chemotherapy resistance, are crucial topics. We will accept original research articles, clinical papers, full and mini-reviews to provide a comprehensive overview of the field. Join us in this endeavor to advance the field and improve patient outcomes through the lens of genomics.

Dr. Ankush Chandra
Dr. Yoshua Esquenazi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • genetics
  • molecular markers
  • precision medicine
  • immunotherapy
  • genomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 6555 KiB  
Article
Construction of a Genetic Prognostic Model in the Glioblastoma Tumor Microenvironment
by Wenhui Wu, Wenhao Liu, Zhonghua Liu and Xin Li
Genes 2025, 16(8), 861; https://doi.org/10.3390/genes16080861 - 24 Jul 2025
Viewed by 244
Abstract
Background: Glioblastoma (GBM) is one of the most challenging malignancies in all of neoplasms. These malignancies are associated with unfavorable clinical outcomes and significantly compromised patient wellbeing. The immunological landscape within the tumor microenvironment (TME) plays a critical role in determining GBM prognosis. [...] Read more.
Background: Glioblastoma (GBM) is one of the most challenging malignancies in all of neoplasms. These malignancies are associated with unfavorable clinical outcomes and significantly compromised patient wellbeing. The immunological landscape within the tumor microenvironment (TME) plays a critical role in determining GBM prognosis. By mining data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and correlating them with immune responses in the TME, genes associated with the immune microenvironment with potential prognostic value were obtained. Method: We selected GSE16011 as the training set. Gene expression profiles were substrates scored by both ESTIMATE and xCell, and immune cell subpopulations in GBM were analyzed by CIBERSORT. Gene expression profiles associated with low immune scores were performed by lasso regression, Cox analysis and random forest (RF) to identify a prognostic model for the multiple genes associated with immune infiltration in GBM. Then we constructed a nomogram to optimize the prognostic model using GSE7696 and TCGA-GBM as validation sets and evaluated these data for gene mutation and gene enrichment analysis. Result: The prognostic correlation between the six genes (MEOX2, PHYHIP, RBBP8, ST18, TCF12, and THRB) and GBM was finally found by lasso regression, Cox regression, and RF, and the online database obtained that all six genes were differentially expressed in GBM. Therefore, a prognostic correlation model was constructed based on the six genes. Kaplan–Meier (KM) survival analysis showed that this prognostic model had excellent prognostic ability. Conclusions: Prognostic models based on tumor microenvironment and immune score stratification and the construction of related genes have potential applications for prognostic analysis of GBM patients. Full article
(This article belongs to the Special Issue Genomics of Glioblastoma: Advances in Diagnosis, Treatment Strategies, and Prognostication)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop